People · Operator
Named in public records as an officer, director or promoter · active 2014–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Juvenescence Ltd | — | Biotechnology | Series C | $121.9M | $324.6M | 2017 |
| Biohaven Pharmaceutical Holding Co Ltd. | — | Pharmaceuticals | Series C | $40.0M | $1.4B | 2016 |
| Kleo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $34.7M | $721.1M | 2016 |
| Causeway Therapeutics Ltd | — | Biotechnology | Series A | $14.3M | $147.7M | 2023 |
| Spinifex Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $6.2M | $191.0M | 2014 |
| Trojan Technologies USA, LLC | — | Biotechnology | Pre-Seed | $255K | $340K | — |
Declan Doogan at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Declan Doogan on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Gregory Bailey | 2 | 8 |
| James Mellon | 1 | 10 |
| Heath Lukatch | 1 | 10 |
| Christopher Jones | 1 | 9 |
| Brent Ahrens | 1 | 7 |
| Stephen Collins | 1 | 5 |
| Greg Bailey | 1 | 5 |
| Denham Eke | 1 | 4 |
| John W. Childs | 1 | 4 |
| Joshua Funder | 1 | 3 |
| John Childs | 1 | 3 |
| David Roblin | 1 | 3 |
| Neil Gibson | 1 | 2 |
| David Spiegel | 1 | 2 |
| Colin Watts | 1 | 2 |
| John Micek | 1 | 2 |
| Alexander Goor | 1 | 2 |
| John Tilton | 1 | 1 |
| Robert Berman, M.D. | 1 | 1 |
| Jim Engelhart | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.